AKASA

AKASAAKASA
AKASA

AKASA

AKASA provides AI-powered automation solutions for healthcare operations, focusing on revenue cycle management to reduce costs and improve efficiency.

DR 632019Active240South San Francisco, United States
Rate

About

AKASA offers an AI-powered platform designed to automate complex administrative tasks within healthcare revenue cycle management. Their Unified Automation™ platform leverages machine learning to streamline processes like prior authorizations, claims processing, and denials management, helping healthcare providers reduce operational costs, improve financial performance, and free up staff for higher-value work.
Frequently asked

What does AKASA do?

AKASA offers an AI-powered platform designed to automate complex administrative tasks within healthcare revenue cycle management. Their Unified Automation™ platform leverages machine learning to streamline processes like prior authorizations, claims processing, and denials management, helping healthcare providers reduce operational costs, improve financial performance, and free up staff for higher-value work.

What is AKASA's revenue?

StartupHub estimates AKASA's annual revenue at $48.4M (range $28.2M to $101.6M, 64% confidence), based on comparable companies in the sector.

What is AKASA's valuation?

StartupHub estimates AKASA's effective valuation at $271.5M (range $175.0M to $420.0M, 10% confidence), based on comparable companies in the sector.

How much funding has AKASA raised?

AKASA has raised a total of $70M in funding. The most recent round on record is Series B.

Where is AKASA headquartered?

AKASA is headquartered in South San Francisco, United States.

When was AKASA founded?

AKASA was founded in 2019.

What industry does AKASA operate in?

AKASA operates in HealthTech, Revenue Cycle Management, Healthcare Automation, Medical Billing, Claims Processing, Prior Authorization.

How many employees does AKASA have?

AKASA has approximately 240 people on record.

HEADCOUNT
240
DOMAIN RATING
63
Comments

No comments yet. Be the first to share your take.